obinutuzumab
obinutuzumab: 45 clinical trials tracked.
obinutuzumab evidence translation
What we can confirm
45 tracked trials
What it means
What to watch
Prepared research question
What is verified about obinutuzumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 12 study sponsors
Related indications
Clinical Trials (45)showing 10 most recent
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Primary endpoint: Safety and Adverse Events (AEs)
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Phase II Radio-GLO Study
Primary endpoint: Complete Response Rate After Radiotherapy and Glofitamab Treatment
Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas
Primary endpoint: Complete Response Rate (CRR) to lisocabtagene maraleucel
An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Primary endpoint: Number of participants with treatment-emergent adverse events
A Randomized Controlled, Two-arm (1:1 Ratio) Phase IIa Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With de Novo Minimal Change Disease
Primary endpoint: Non-inferiority of obinutuzumab to SoC predniso(lo)ne taper: Proportions of patients achieving remission (complete or partial) of MCD at 8 weeks
TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Primary endpoint: Complete response rate
Obinutuzumab, Zanubrutinib, and Lenalidomide as First-Line Therapy for Mantle Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multicenter Study
Primary endpoint: complete response rate (CR)
A Phase 1b Study of Glofitamab in CNS Lymphoma
Primary endpoint: Incidence of grade 3 or higher non-hematologic toxicity that does not resolve to grade 1 or better within 7 days
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Primary endpoint: Safety and adverse events
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Primary endpoint: Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) for Arm A versus Arm D